Aurobindo Pharma had emerged as the highest bidder for acquisition of Natrol Inc, US
Aurobindo Pharma said Plethico will pay it $23.3 million to settle a dispute related to the acquisition of US-based Natrol.
According to a PTI report, Aurobindo Pharma’s 100-per cent subsidiary Aurobindo Pharma US completed the acquisition of Natrol from Plethico for $132.5 million on December 5, 2014.
On April 6, 2015, Natrol had approached the Delaware Bankruptcy Court with certain discrepancies and non-performance of obligations by erstwhile owner Plethico with regard to the deal.
“Based on the discussions, a settlement agreement has been reached, wherein Plethico Group would assign $23.3 million in cash in milestone payments, certain global IP rights and other assets,” Aurobindo Pharma said in a BSE filing.
Aurobindo Pharma had emerged as the highest bidder for acquisition of Natrol Inc, US.
The acquisition included manufacturing assets, personnel, commercial infrastructure, including nutraceutical brands in the US of Natrol along with an agreement to take certain liabilities.
- Advertisement -
Comments are closed.